Tarsons Products reported a consolidated net loss of ₹14.44 million for the quarter ended June 30, 2026 (Q1FY26), compared to a net profit of ₹17.83 million in Q1FY25. The decline was primarily driven by increased depreciation and amortization expenses and higher finance costs, which outweighed revenue growth. Despite the consolidated loss, the standalone entity recorded a net profit of ₹6.80 million, up from ₹35.70 million in the corresponding quarter of the previous year. The divergence between standalone and consolidated results highlights the financial performance of its overseas subsidiaries.

The Board of Directors approved the unaudited financial results on August 10, 2026. Price Waterhouse Chartered Accountants LLP served as the statutory auditor, issuing a limited review report under Standard on Review Engagements (SRE) 2410. The filing also disclosed that two subsidiaries, Nerbe plus GmbH & Co. KG and Nerbe R&D GmbH, were not reviewed by their auditors but were deemed immaterial to the Group, contributing a total income of ₹15.66 million and a net loss of ₹17.71 million.

Financial Performance

Consolidated revenue from operations rose to ₹1,102.42 million in Q1FY26, up from ₹913.84 million in Q1FY25. Total income reached ₹1,162.21 million, supported by other income of ₹59.79 million. However, total expenses surged to ₹1,175.45 million from ₹916.68 million year-on-year. Depreciation and amortization expenses jumped to ₹270.20 million from ₹199.36 million, while finance costs increased to ₹62.65 million from ₹50.71 million. Employee benefits expense also rose to ₹212.13 million from ₹178.62 million.

Standalone revenue grew to ₹861.47 million from ₹712.79 million in Q1FY25. Standalone total income was ₹929.01 million against expenses of ₹919.79 million, resulting in a profit before tax of ₹9.22 million. After a tax expense of ₹2.42 million, the standalone net profit stood at ₹6.80 million, compared to ₹35.70 million in Q1FY25.

Segment-wise Breakdown

The Group operates in two primary geographical segments: India and Germany. India contributed ₹861.14 million to segment revenue in Q1FY26, up from ₹712.68 million in Q1FY25. Germany’s revenue increased to ₹241.28 million from ₹200.96 million. Segment results before exceptional items, interest, tax, and depreciation (EBITDA) for India were ₹294.35 million, while Germany reported ₹24.14 million.

Governance and Disclosures

Tarsons disclosed that during FY26, it paid excess managerial remuneration totaling ₹41.39 million, comprising ₹19.67 million to the Managing Director, ₹20.51 million to the Whole Time Director, and ₹1.21 million to other directors. This exceeds the limits under Section 197 of the Companies Act, 2013. The company seeks shareholder approval for a waiver via a special resolution at its upcoming Annual General Meeting.

Additionally, the Board fixed September 24, 2026, as the date for the 43rd Annual General Meeting (AGM), to be held via video conferencing. The cut-off date for e-voting is set for September 17, 2026. The filing also noted the statutory impact of new labour codes implemented in November 2025, which resulted in an exceptional item charge of ₹11.27 million in FY26 due to past service cost recognition under Ind AS 19.

What the Numbers Show

The widening gap between standalone profitability and consolidated losses underscores the pressure on Tarsons’ overseas operations. While the Indian segment delivered strong EBITDA growth, the German subsidiary’s contribution margin appears thin relative to its revenue base. The significant jump in depreciation costs—likely linked to recent capital expenditures or asset revaluations—has heavily impacted the bottom line, turning a previously profitable quarter into a loss-making one on a consolidated basis. Investors should monitor the outcome of the special resolution regarding excess remuneration, as it reflects ongoing governance adjustments within the management structure.

Tarsons Products Limited reported a 21% year-on-year revenue growth to ₹110.2 crore for the consolidated quarter ended June 30, 2026 (Q1FY27), driven by strong domestic demand and a rebound in exports. Despite a net loss of ₹1.4 crore due to higher raw material costs and expenses from new manufacturing facilities, the company’s Cash Profit After Tax (PAT) grew 18% to ₹25 crore, signaling underlying operational resilience.

The results were disclosed in an investor presentation filed with the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE) on August 11, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing provides detailed insights into the financial performance and strategic initiatives undertaken during the quarter.

Financial Performance Highlights

Consolidated revenue from operations stood at ₹110.2 crore in Q1FY27, compared to ₹91.4 crore in the corresponding quarter of the previous year (Q1FY26). The growth was broad-based, with domestic business delivering 17% year-on-year growth supported by a revival in demand across product categories. Exports rebounded strongly, growing 29% year-on-year following geopolitical tensions that impacted the previous quarter.

Standalone revenue also grew 21% to ₹86 crore. However, margins were pressured by increased raw material prices stemming from supply chain disruptions and expenses related to the new Panchla and Amta facilities. These facilities are expected to contribute meaningfully to revenue from FY28 and FY29.

Operational Updates and Strategic Outlook

Aryan Sehgal, Promoter and Whole Time Director, attributed the growth to deeper customer penetration and improving underlying demand. He noted that while the Amta facility has commenced commercial supplies, the cell culture lines at the Panchla facility are expected to be commissioned towards the end of Q2FY27. This expansion aims to address evolving customer needs and increase the addressable market.

The company continues to invest in automation and capacity expansion to strengthen its competitive positioning. With over four decades of brand equity, Tarsons remains focused on sustainable growth over the next three to five years, leveraging its wide distribution network and diverse product portfolio including consumables, reusables, and benchtop instrumentation.

What the Numbers Show

The divergence between the negative Net PAT and the positive, growing Cash PAT highlights the impact of non-cash items such as accelerated depreciation and finance costs associated with capital expenditure on new facilities. This suggests that core operational cash generation remains robust despite short-term profitability pressures from expansion-related investments.